We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 0.51% | 39.70 | 39.50 | 39.70 | 39.75 | 38.10 | 39.05 | 1,198,676 | 16:29:46 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 233.53 | 214.44M |
Consolidated Income Statement
Year Year ended ended 31 December 31 December 2014 2013 Note Restated* GBP 000s GBP 000s ------------------------------------- ---- ------------ --------------------- Revenue 43,536 45,275 Cost of sales (18,493) (17,944) ------------------------------------- ---- ------------ --------------------- Gross profit 25,043 27,331 ------------------------------------- ---- ------------ --------------------- Operating expenses Administration and marketing expense (12,510) (12,917) Amortisation of intangible assets (488) (422) Share-based employee remuneration (571) (632) Share of joint venture profits / (losses) 319 (48) ------------------------------------- ---- ------------ --------------------- (13,250) (14,019) ------------------------------------- ---- ------------ --------------------- Operating profit excluding exception item 11,793 13,312 Exceptional item: impairment of intangible asset (622) - ------------------------------------- ---- ------------ --------------------- Operating profit 11,171 13,312 Finance costs Interest payable and similar charges 2 (1,090) (1,281) Interest income 2 48 50 Other finance income / (charges) 2 28 (72) (1,014) (1,303) ------------------------------------- ---- ------------ --------------------- Profit on ordinary activities before taxation 10,157 12,009 Taxation 3 (1,772) (2,425) ------------------------------------- ---- ------------ --------------------- Profit for the year attributable to equity shareholders 8,385 9,584 ------------------------------------- ---- ------------ --------------------- Earnings per share Basic (pence) 5 3.17 3.82 Diluted (pence) 5 3.16 3.68 ------------------------------------- ---- ------------ ---------------------
*Restated due to the adoption of IFRS 11, please see note 11.
Consolidated Statement of Comprehensive Income
Year ended Year ended 31 December 31 December 2014 2013 GBP 000s GBP 000s Profit for the period 8,385 9,584 Other comprehensive income Other items recognised directly in equity Items that may be reclassified to profit or loss Interest rate swaps - cash flow hedge (572) 443 Deferred tax on interest rate swaps 119 (93) Foreign exchange translation 7 - differences Share of joint venture OCI (8) - Total comprehensive income for the period 7,931 9,934 ------------------------------------- ------------- -------------
Consolidated Statement of Financial Position
31 December 31 December 31 December 31 December 2014 2014 2013 2013 Restated* Restated* Note GBP 000s GBP 000s GBP 000s GBP 000s ----------------------------- ---- ----------- ----------- ----------- ----------- Assets Non-current assets Intangible assets 6 88,875 87,111 Property, plant and equipment 396 592 Joint Venture Investment 1,271 533 Joint Venture Receivable 1,462 1,462 Derivative financial instruments - 443 Deferred tax asset 194 - 92,198 90,141 Current assets Inventories 5,914 5,468 Trade and other receivables 7 8,322 10,641 Cash and cash equivalents 10 1,434 687 15,670 16,796 Total assets 107,868 106,937 ----------------------------- ---- ----------- ----------- ----------- ----------- Equity Ordinary share capital 2,641 2,641 Share premium account 29,388 29,380 Share option reserve 1,995 1,424 Reverse takeover reserve (329) (329) Other reserve (103) 350 Retained earnings 37,188 31,202 ----------------------------- ---- ----------- ----------- ----------- ----------- Total equity 70,780 64,668 Liabilities Non-current liabilities Long term financial liabilities 19,235 20,881 Deferred tax liability 6,309 6,294 Provisions for other liabilities - 199 Derivative financial instruments 129 - ----------------------------- ---- ----------- ----------- ----------- ----------- 25,673 27,374 Current liabilities Cash and cash equivalents 10 414 2,125 Financial liabilities 2,895 2,895 Corporation tax 959 1,154 Trade and other payables 8 6,920 8,531 Provisions for other liabilities 227 190 11,415 14,895 Total liabilities 37,088 42,269 Total equity and liabilities 107,868 106,937 ----------------------------- ---- ----------- ----------- ----------- -----------
*Restated due to the adoption of IFRS 11, please see note 11
Consolidated Statement of Changes in Equity
Ordinary Share Share Reverse share premium option takeover Other Retained Total capital account reserve reserve reserve earnings equity GBP GBP 000s GBP 000s GBP 000s GBP 000s GBP 000s GBP 000s 000s Balance 1 January 2014 2,641 29,380 1,424 (329) 350 31,202 64,668 -------------------------- --------- --------- --------- ---------- --------- ---------- -------- Issue of shares - 8 - - - - 8 Dividend paid - - - - - (2,398) (2,398) Share options charge - - 571 - - - 571 -------------------------- --------- --------- --------- ---------- --------- ---------- -------- Transactions with owners - 8 571 - - (2,398) (1,819) -------------------------- --------- --------- --------- ---------- --------- ---------- -------- Profit for the period - - - - - 8,385 8,385 Other comprehensive income Interest rate swaps - cash flow hedge - - - - (572) - (572) Deferred tax on interest rate swap - - - - 119 - 119 Foreign exchange translation differences - - - - - (1) (1) -------------------------- --------- --------- --------- ---------- --------- ---------- -------- Total comprehensive
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions